Hypermethylation of O6-MGMT was associated with better survival through the first 60 months of follow-up, the risk ratio was 0.36 (95% CI 0.15–0.87, p= 0.049) and still remained significant after adjusting for tumor stage and differentiation (p=0.023), see Table III. Here, MGMT is linked to neoplasm.